Definition of Alectinib. Meaning of Alectinib. Synonyms of Alectinib

Here you will find one or more explanations in English for the word Alectinib. Also in the bottom left of the page several parts of wikipedia pages related to the word Alectinib and, of course, Alectinib synonyms and on the right images related to the word Alectinib.

Definition of Alectinib

No result for Alectinib. Showing similar results...

Meaning of Alectinib from wikipedia

- Alectinib (INN), sold under the brand name Alecensa, is an anticancer medication that is used to treat non-small-cell lung cancer (NSCLC). It blocks the...
- alectinib in efficacy, while being active against some resistant mutations such as the common G1202R mutation that provides resistance to alectinib....
- which can be treated with ALK inhibitors crizotinib, or its successors alectinib, brigatinib, and ceritinib. Those treated with ALK inhibitors who relapse...
- and vomiting, licensed by Eisai Co. and Helsinn Therapeutics. Alecensa (alectinib), for ALK-positive non-small cell lung cancer. Aloxi (palonosetron), for...
- Vemurafenib Hoffmann-La Roche Erdheim-Chester disease with BRAF V600 mutation Alectinib Hoffmann-La Roche ALK-positive, metastatic non-small cell lung cancer...
- 2035 MA 2006 Linagliptin 2011 2031 SM 2007 Apixaban 2012 2032 SM 2007 Alectinib 2014 2014 SM 2007 Sofosbuvir 2007, Raymond F. Schi****. N/A N/A N/A SM...
- chemotherapy. In February 2016, the J-ALEX phase III study comparing alectinib with crizotinib ALK-positive metastatic NSCLC was terminated early because...
- Dabrafenib L01EC03 Encorafenib L01ED01 Crizotinib L01ED02 Ceritinib L01ED03 Alectinib L01ED04 Brigatinib L01ED05 Lorlatinib L01EE01 Trametinib L01EE02 Cobimetinib...
- to treat metastatic melanoma caused by BRAF mutation. 2015: Alecensa (alectinib): Treatment for non-small cell lung cancer (NSCLC). 2016: Venclexta (venetoclax):...
- Regorafenib Semaxanib Sorafenib Sunitinib Tivozanib Toceranib Vandetanib ALK Alectinib Brigatinib Ceritinib Crizotinib Ensartinib Lorlatinib RET inhibitors:...